Starnberg, 2 July 2025
The PARI Group is restructuring its leadership team. On 1 July 2025, Dr Stefan Seemann, previously Managing Director of PARI Pharma GmbH, assumed the role of Chief Executive Officer (CEO) of the PARI Group. Together with Anja Zschernig (CFO), Dr Seemann is to take over the management of PARI Medical Holding GmbH.
With his 25-year track record in various leadership roles at PARI and four years as Managing Director of PARI Pharma GmbH, Dr Stefan Seeman brings strategic foresight and in-depth knowledge of the company, making him the ideal candidate for the new role.
“Many patients, doctors and pharmacist across the globe place their trust in our inhalation devices, medications and inhalation solutions. I am delighted that working hand-in-hand with my colleagues on the Management Board, in my new role as CEO I can continue to contribute to PARI's ongoing success,” says Dr Stefan Seemann.
Michael Hahn is to succeed Dr Seemann as Managing Director of PARI Pharma GmbH. A member of the PARI team since 2006, Michael Hahn was most recently Vice President of eFlow Partnering & Strategy at PARI Pharma GmbH. He comes to the position with many years of experience, far-reaching expertise and a strong network to our partners.
PARItec GmbH, the production company within the group, is also to see a change in management: Peter Cabell, who has previously held the position of Director of Production of Aerosol Heads at PARI Pharma GmbH, is to take over the helm from Jürgen Müller, who is to take well-earned retirement.
Dr Frank Bredl is to remain Managing Director of PARI GmbH, while Derek Kish will continue in his role as President of PARI Respiratory Equipment, Inc. (PRE), the US subsidiary.
With its personnel reshuffle, the PARI Group is strengthening its management structure to keep it fit for the future and position itself for sustained success now and in the years to come.
Download this article as a PDF
As a manufacturer of medical devices with a focus on inhalation devices, PARI is the market leader in Germany, having established itself over decades as a trusted brand among doctors, pharmacies and patients, while its success in the cystic fibrosis segment has positioned the company as world market leader.
PARI was founded in Wuppertal in 1906 and now has its headquarters in Starnberg. Always an independent and privately owned company, the PARI Group is under the umbrella of PARI Medical Holding with presidents Dr Stefan Seemann and Anja Zschernig and is organised into several subsidiaries:
In addition, there are international branch offices and a worldwide distribution network.
With a workforce of around 750 and a management team that has been stable for many years, the company can look back on a history of more than 100 years in business. It is where tradition and innovation meet to deliver well thought-out and effective product lines with an excellent reputation. Clinically proven, tried and tested nebulisers and inhalation devices made in Germany with affirmed performance have been used in countless pivotal studies and have won over medical specialists and users for decades.
Among the most well-known products are the PARI BOY®, which is synonymous with inhalation therapy and has been on the market for over 50 years and is on its 8th generation, as well as the eFlow®rapid nebuliser based on vibrating membrane technology supplemented by a multitude of drug-specific applications in respiratory diseases.
PARI Medical Holding GmbH
Public Relations
Moosstrasse 3, 82319 Starnberg
GERMANY
Tel.: 0049 8151 279 0
Fax: 0049 8151 279 6119
Email: publicrelationspari.com
© 2025 PARI GmbH Spezialisten für effektive Inhalation
